Phase 2 Randomised Study of Bulevirtide as Monotherapy or Combined With Peg-IFNα-2a as Treatment for Chronic Hepatitis Delta.
Saved in:
| Title: | Phase 2 Randomised Study of Bulevirtide as Monotherapy or Combined With Peg-IFNα-2a as Treatment for Chronic Hepatitis Delta. |
|---|---|
| Authors: | Lampertico P; Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.; CRC 'A. M. And A. Migliavacca' Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy., Bogomolov PO; State Budgetary Institution of Health Care of Moscow Region, Moscow Regional Research Clinical Institute n.a. M.F. Vladimirsky, Moscow, Moscow, Russian Federation., Chulanov V; National Medical Research Center of Tuberculosis and Infectious Diseases, Moscow, Russian Federation.; Sechenov First Moscow State Medical University, Moscow, Russian Federation., Stepanova T; Limited Liability Company 'Clinic of Modern Medicine,' Moscow, Moscow, Russian Federation., Morozov V; LLC Medical Company Hepatolog, Samara, Russian Federation., Allweiss L; Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.; German Center for Infection Research (DZIF), Hamburg-Lübeck-Borstel-Riems, Borstel, Germany., Dandri M; Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.; German Center for Infection Research (DZIF), Hamburg-Lübeck-Borstel-Riems, Borstel, Germany., Burhenne J; Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University Hospital, Heidelberg, Germany.; German Center for Infection Research (DZIF), Heidelberg, Germany., Blank A; Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University Hospital, Heidelberg, Germany.; German Center for Infection Research (DZIF), Heidelberg, Germany., Ciesek S; Institute for Medical Virology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt, Germany.; German Centre for Infection Research, External Partner Site, Frankfurt, Germany., Elsner C; Institute for Virology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany., Dittmer U; Institute for Virology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany., An Q; Gilead Sciences Inc., Foster City, California, USA., Manuilov D; Gilead Sciences Inc., Foster City, California, USA., Da BL; Gilead Sciences Inc., Foster City, California, USA., Flaherty JF; Gilead Sciences Inc., Foster City, California, USA., Urban S; German Center for Infection Research (DZIF), Heidelberg, Germany.; Department of Infectious Diseases, Molecular Virology, Heidelberg University Hospital, Heidelberg, Germany., Wedemeyer H; Department of Gastroenterology, Hepatology, Endocrinology, and Infectious Diseases, Hannover Medical School, Hannover, Germany.; German Center for Infection Research (DZIF), Partner Site Hannover-Braunschweig, Braunschweig, Germany.; Excellence Cluster RESIST and D-Solve Consortium, Hannover, Germany. |
| Source: | Liver international : official journal of the International Association for the Study of the Liver [Liver Int] 2025 Feb; Vol. 45 (2), pp. e70008. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II; Multicenter Study; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 101160857 Publication Model: Print Cited Medium: Internet ISSN: 1478-3231 (Electronic) Linking ISSN: 14783223 NLM ISO Abbreviation: Liver Int Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1478-3231 |
|---|---|
| DOI: | 10.1111/liv.70008 |
